Review on oral suspensions for paediatric patient

Authors

  • Tanmoy Bhattacharjee Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India 737136
  • NIshan Hazra Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India 737136
  • Saurav Kr. Sarma Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India 737136
  • Aditya Pradhan Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India 737136
  • Teeganla Subba Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India 737136

Keywords:

Paediatric, formulation, quantifiable dosage form, physical stability, chemical stability, excipients

Abstract

Majority of the conventional dosage form are unacceptable for paediatric patients, since have different developmental needs and dosing requirements than other segments of the population. The prerequisites for a quantifiable dosage form to provide depending on bodyweight and also flavour profile are two of the obstacles specific to paediatric oral formulations, making them quite scientifically difficult to design. The biopharmaceutical and physicochemical properties of the active pharmaceutical ingredient such as physical or chemical stability, solubility are determine which formulation is suitable. More regulatory incentives have recently led to an increase in the development of paediatric formulations. The aim of this review is to provide the information about the recent approaches to oral suspensions, its various limitations and advantages, the rationale on formulation of oral suspension, different excipient used in formulation, some marketed formulations.

References

Bruns C, Ober M. Development and Preparation of Oral Suspensions for Paediatric Patients – a Challenge for Pharmacists. Pharm Technol Hosp Pharm 2018; 3:113–9. https://doi.org/10.1515/pthp-2018-0008.

Strickley RG. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007. J Pharm Sci 2019;108:1335–65. https://doi.org/10.1016/j.xphs.2018.11.013.

Bhandare PS, Yadav A V. a Review on “Dry Syrups for Paediatrics.” Int J Curr Pharm Res 2016;9:25. https://doi.org/10.22159/ijcpr.2017v9i1.16789.

Cram A, Breitkreutz J, Desset-Brèthes S, Nunn T, Tuleu C. Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009;365:1–3. https://doi.org/10.1016/j.ijpharm.2008.09.015.

Psimadas D, Georgoulias P, Valotassiou V, Loudos G. Molecular Nanomedicine Towards Cancer : J Pharm Sci 2012;101:2271–80. https://doi.org/10.1002/jps.

Annereau M, Hinterlang M, Bienayme H, Vassal G, Pinon A, Schmitt M, et al. Development of a Hospital Compounded, Taste‐Masked, Temozolomide Oral Suspension and 5‐Year Real‐Life Experience in Treating Paediatric Patients. Pharmaceuticals 2022;15:1–15. https://doi.org/10.3390/ph15050555.

Elkayal O, Spriet I, Uyttebroeck A, Colita A, Annaert P, Allegaert K, et al. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. Ther Drug Monit 2021;43:512–8. https://doi.org/10.1097/FTD.0000000000000877.

Lopez FL, Ernest TB, Tuleu C, Gul MO. Formulation approaches to pediatric oral drug delivery: Benefits and limitations of current platforms. Expert Opin Drug Deliv 2015; 12: 1727–40.

https://doi.org/10.1517/17425247.2015.1060218.

Raymond J, Aujard Y. N Osocomial I Nfections in P Ediatric P Atients : a E Uropean , M Ulticenter P Rospective S Tudy. Infect Control Hosp Epidemiol 2000;21:260–3. https://doi.org/10.35248/2153-2435.22.13.685.

Abu-Khalaf N, Zaid AN, Jaradat N, Alkilany A, Rumaila BA, Ramahi R Al, et al. The taste of commercially available clarithromycin oral pharmaceutical suspensions in the palestinian market: Electronic tongue and in vivo evaluation. Sensors (Switzerland) 2018;18:1–10. https://doi.org/10.3390/s18020454.

Zahn J, Hoerning A, Trollmann R, Rascher W, Neubert A. Erratum: Zahn et al. Manipulation of medicinal products for oral administration to paediatric patients at a german university hospital: An observational study. Pharmaceutics 2020, 12, 583. Pharmaceutics 2021;13. https://doi.org/10.3390/pharmaceutics13070939.

Buontempo F, Bernabeu E, Glisoni RJ, Quiroga E, Bregni C, Chiappetta DA. Carvedilol stability in paediatric oral liquid formulations. Farm Hosp 2010;34:293–7. https://doi.org/10.1016/j.farma.2010.01.002.

Helin-Tanninen M, Autio K, Keski-Rahkonen P, Naaranlahti T, Järvinen K. Comparison of six different suspension vehicles in compounding of oral extemporaneous nifedipine suspension for paediatric patients. Eur J Hosp Pharm 2012;19:432–7. https://doi.org/10.1136/ejhpharm-2012-000159.

Downloads

Published

30-06-2023

How to Cite

Bhattacharjee, T., Hazra, N., Sarma, S. K., Pradhan, A., & Subba, T. (2023). Review on oral suspensions for paediatric patient. UNIVERSAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 9(1), 11–16. Retrieved from http://ujpsr.in/index.php/journal/article/view/6

Issue

Vol. 9 No. 1 (2023)

Section

Articles

License

Copyright (c) 2023 Tanmoy Bhattacharjee, NIshan Hazra, Saurav Kr. Sarma, Aditya Pradhan, Teeganla Subba

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.